AVGR - Avinger, Inc.
| Previous Close | 1.2900 |
| Open | 1.2700 |
| Bid | 1.2300 x 900 |
| Ask | 1.2800 x 1000 |
| Day's Range | 1.2000 - 1.2700 |
| 52 Week Range | 0.7700 - 12.6000 |
| Volume | 65,667 |
| Avg. Volume | 469,460 |
| Market Cap | 13M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.5960 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
- Thomson Reuters StreetEvents
Edited Transcript of AVGR earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Avinger Inc Earnings Call
- Zacks
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys
- Zacks
What Bargain Hunting? Tap 5 Stocks With Rising P/E
Bet on these top-ranked stocks with rising P/E for outsized gains.
- GlobeNewswire
Avinger Reports Third Quarter 2019 Financial Results
Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 --.
- Zacks
Try Rising P/E Investing With 5 Top-Ranked Stocks
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
- ACCESSWIRE
Avinger to Announce Third Quarter 2019 Financial Results on November 5, 2019
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
- Zacks
Avinger (AVGR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Avinger (AVGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks
Top Ranked Momentum Stocks to Buy for October 24th
Top Ranked Momentum Stocks to Buy for October 24th
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- Zacks
Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- ACCESSWIRE
Avinger Expands US Reach with Seven New Accounts in Third Quarter
REDWOOD CITY, CA / ACCESSWIRE / October 9, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the launch of seven new Lumivascular centers during the third quarter, including sites in the high-volume PAD markets of Florida, Georgia and Arizona. This growth in new accounts is the result of continued expansion of Avinger's sales team and strong market demand for the Company's Pantheris and Pantheris SV image-guided atherectomy products. "We are excited to report the launch of seven new clinical centers using Avinger's best-in-class Lumivascular platform during the third quarter, as we continue to expand our geographic reach in the U.S. and bring highly differentiated new products to market," said Jeff Soinski, Avinger's President and CEO.
- ACCESSWIRE
Avinger Announces Full Commercial Launch of Pantheris SV
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the full commercial launch of the Pantheris SV (small vessel) image-guided atherectomy system in the U.S. All current and prospective Lumivascular accounts are now eligible to order the Pantheris SV device. Avinger launched Pantheris SV at select Avinger sites in late July in order to demonstrate the product's ease of use and efficiency across a variety of user approaches and vascular conditions in a real-world clinical setting, as well as train clinical support and sales personnel in best practices with this new device.
- ACCESSWIRE
Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24
REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that ...
- ACCESSWIRE
Avinger Announces Commercial Launch and First Patients Treated in Hong Kong
REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products in Hong Kong. Avinger has an exclusive distribution agreement with Integmed Ltd. for the sale and marketing of Avinger’s Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO) crossing systems in Hong Kong. Dr. Yiu Che Chan, a highly-experienced vascular surgeon and a clinical associate professor at The University of Hong Kong, performed the first four cases using Lumivascular technology in Hong Kong at Queen Mary Hospital.
- ACCESSWIRE
Avinger Supports Peripheral Artery Disease (PAD) Awareness Month with Physician and Patient Programs in September
REDWOOD CITY, CA / ACCESSWIRE / September 4, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), urges greater awareness for this disease state in support of PAD Awareness Month in September. Avinger plans to support PAD Awareness Month through the distribution of informational articles and content related to PAD throughout September, directed both at physicians and patients. In the United States alone, up to 20 million individuals are estimated to suffer from PAD, yet the condition is often under-recognized, under-diagnosed, and under-treated in part because many PAD patients are asymptomatic or dismiss their symptoms as normal age-related complications.
- ACCESSWIRE
Avinger Announces 50th Patient Treated in Pantheris SV Initial Launch
REDWOOD CITY, CA / ACCESSWIRE / August 29, 2019 / Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported significant progress in the initial U.S. launch of the Pantheris SV (small vessel) image-guided atherectomy system. To date, physicians in 10 clinical centers have used Pantheris SV to successfully treat 50 patients in the U.S. Based on positive clinical reports and physician feedback from these initial sites, the Company is ramping production of Pantheris SV in preparation for full commercial launch, which is anticipated to begin in September. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in smaller diameter vessels.
- GlobeNewswire
Avinger Closes $4.5 Million Equity Offering
Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Attention: Prospectus Department, 810 7th Avenue, 18th floor, New York, NY 10019, by email at prospectus@aegiscap.com, or by telephone at (212) 813-1010.This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
- GlobeNewswire
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.
- GlobeNewswire
Avinger Announces Proposed Underwritten Public Offering of Common Stock
Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of the Company’s sales and marketing organizations and efforts, intellectual property protection and enforcement, payment of principal and interest on debt and capital expenditures.
- ACCESSWIRE
Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference
REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivascular technology at the annual AMP (Amputation Prevention Symposium) conference occurring last week.
- Thomson Reuters StreetEvents
Edited Transcript of AVGR earnings conference call or presentation 31-Jul-19 8:30pm GMT
Q2 2019 Avinger Inc Earnings Call
- GlobeNewswire
Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019
Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a.
- GlobeNewswire
Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States
Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in small diameter vessels.
- GlobeNewswire
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019
REDWOOD CITY, Calif., July 26, 2019 -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided,.
- ACCESSWIRE
Avinger Announces Presentations by Key Opinion Leaders at CVC 2019
REDWOOD CITY, CA / ACCESSWIRE / July 16, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced five podium presentations and a live case featuring the Company’s Lumivascular technology at the annual CVC conference occurring last week.
